ReviewJournal of molecular medicine (Berlin, Germany)2025
Specialized pro-resolving mediators: key regulators in placental function and pregnancy complications.
Review in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Targeting NF-κB Signaling in Preterm Labor: Molecular Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Differential Regulation of Inflammatory and Pro-Resolving Lipid Mediators in Chronic Coronary Syndrome Across Cardiometabolic Phenotypes.International journal of molecular sciences · 2026Observational
- Metabolic Reprogramming at the Maternal-Fetal Interface: Insights from Decidual Stromal Cells and Trophoblasts in Healthy Pregnancy Versus Recurrent Pregnancy Loss.International journal of molecular sciences · 2026Review
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- Unsaturated fatty acids as immunometabolic modulators in high-risk pregnancies: mechanisms, clinical evidence, and translational perspectives.Frontiers in pharmacology · 2026Review
- Article
- Regulatory T cells in pregnancy disorders: a multi-dimensional framework for biomarkers and therapeutic strategies.Frontiers in immunology · 2026Review
- Clinical significance of plasma SERPINA3 in patients with missed miscarriage.Frontiers in medicine · 2026Article
- Nouveau benzo-mimetics of 17R-Resolvin D2 are potent resolution agonists for inflammation.iScience · 2025Article
- Docosahexaenoic Acid (DHA) Decreases IL-6 and Prostaglandin-Endoperoxide Synthase 2 mRNA Expression and IL-6 Protein Release, While Increasing Resolvin D1 and CXCL8 mRNA Expression and Protein Release in BovineEndometrial Cells.Animals : an open access journal from MDPI · 2025Article
- Oxidative Stress and Inflammation in Uterine-Vascular Adaptation During Pregnancy.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Specialized pro-resolving mediators (SPMs) are bioactive lipids derived from essential fatty acids that play a key role in resolving inflammation and modulating immune responses, thereby maintaining tissue homeostasis in various physiological contexts, including pregnancy. In healthy pregnancies, inflammation is a biological response necessary for vascular remodeling, embryo implantation as well as delivery and an increase in SPMs such as lipoxin A4 (LXA4) and resolvin D1 (RvD1) supports homeostasis and facilitates inflammation resolution. However, pregnancy complications such as spontaneous abortion, fetal growth restriction (FGR), and preeclampsia are often associated with disrupted SPM levels and receptor activity. In spontaneous abortion, altered SPM levels are linked to impaired endometrial receptivity, defective trophoblast invasion, poor epithelial-to-mesenchymal transition, and enhanced inflammation. Similarly, FGR is associated with reduced LXA4 levels, which contribute to placental vascular dysfunction and impaired trophoblast migration. Preeclampsia is characterized by dysregulated SPM levels and a pro-inflammatory environment, indicating insufficient resolutive activity. Therapeutic approaches to enhance SPM levels, such as aspirin-triggered lipoxins and omega-3 fatty acid supplementation, have demonstrated potential benefits. However, inconsistent clinical outcomes highlight the need for personalized treatment strategies. This review explores the role of SPMs in pregnancy, focusing on their molecular mechanisms and the development of targeted supplementation strategies to optimize their protective effects in managing high-risk pregnancies. KEY MESSAGES: Physiological pregnancies involve a gradual increase in SPM levels. LXA4 and RvD1 may have a context-dependent role in placentation by negatively regulating endometrial decidualization, trophoblast EMT and invasion, which contributes to spontaneous abortion, while positively regulating endothelial function, trophoblast survival and M2-macrophage polarization, which supports pregnancy. SPMs are essential to preserve endothelial integrity and support trophoblast proliferation, and appear downregulated in FGR. Preeclampsia is correlated with dysregulated SPM levels and a reduced LXA4/TNFα ratio, which suggests insufficient anti-inflammatory action. Therapeutic strategies that enhance SPMs production such as aspirin and DHA supplementation show considerable promise, particularly in preventing complications in high-risk pregnancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.